SummaryIfosfamide is one of the most effective cytostatics for the treatment of non-small cell and small cell bronchial carcinomas. For non-small cell carcinomas in particular, the administration of 1.5–2.0 g/m2 B. S. A. on 5 successive days at intervals of 3–4 weeks has been found to be optimal. Ifosfamide has been used in combination with one or two cytotoxic agents for both small cell and non-small cell carcinomas. Higher remission rates and longer periods of remission are achieved through this combined chemotherapy than with monochemotherapy. This result is also reflected in longer median survival periods for the successfully treated patients. The results of the chemotherapy with ifosfamide combinations are comparable in non-small cell and small cell bronchial carcinomas with those obtained using the cis-platinum combinations. Because of the considerably better tolerance the ifosfamide combinations are to be preferred, however. This particularly applies when cis-platinum is used in a moderate to high single dose.Ifosfamide combinations have increased the range of effective therapeutic regimens available for small cell bronchial carcinoma. They also suggest themselves as primary therapy for patients in whom the use of anthracycline-antibiotics is contraindicated, they have proved to be valuable partners in sequential-alternating chemotherapy and also to be second-line treatment in cases where there has been no response to anthracycline combinations.